U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,783.90
    +21.20 (+1.20%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    48,424.44
    -5,004.05 (-9.37%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Chiasma Stock Shoots Up On Being Acquired By Amryt Pharma In All Stock Deal

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Amryt Pharma (NASDAQ: AMYT) has agreed to acquire Chiasma Inc (NASDAQ: CHMA) in an all-stock combination. Each Chiasma shares will be exchanged for 0.396 Amryt American Depositary Shares, each representing five Amryt ordinary shares.

  • The transaction is expected to accelerate and diversify Amryt's growing revenues, and Amryt expects to deliver estimated annual cost synergies of approximately $50M.

  • Dr. Joe Wiley, Chief Executive Officer of Amryt, said, "this deal further solidifies our position as a global leader in treating rare and orphan conditions."

  • The combined business will have three approved commercial products, and the combined portfolio of products offers a pathway to a potential $1 billion of peak revenues.

  • Lead development candidate, Oleogel-S10, is currently progressing through the regulatory process in the US and EU and, if approved, will bring a portfolio of commercial products to four.

  • Management will host a webcast and conference call today at 8:30 A.M. ET.

  • Price Action: AMYT shares fell 0.31% at $12.80, CHMA shares are up 37% to $3.88 in the premarket trading session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.